Author:
Bartsch Rupert,Rinnerthaler Gabriel,Petru Edgar,Egle Daniel,Gnant Michael,Balic Marija,Sliwa Thamer,Singer Christian
Abstract
SummaryApproximately 15% of newly diagnosed breast cancer patients have neither hormone receptors expression nor HER2 overexpression and/or HER2/neu gene amplification. This subtype of breast cancer is known as Triple Negative Breast Cancer (TNBC), and carries a significantly elevated risk of local and distant recurrence. In comparison with other breast cancer subtypes, there is a higher rate of visceral and brain metastases. The majority of metastases of TNBC are diagnosed within three years after initial breast cancer diagnosis. While there have been major advances in hormone-receptor- positive and in human epidermal growth factor receptor 2 (HER2)-positive disease over the past two decades, only limited improvements in outcomes for patients with triple negative breast cancer (TNBC) have been observed. A group of Austrian breast cancer specialists therefore convened an expert meeting to establish a comprehensive clinical risk-benefit profile of available mTNBC therapies and discuss the role sacituzumab govitecan may play in the treatment algorithm of the triple-negative breast cancer patients.
Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Reference108 articles.
1. Afifi AM, Saad AM, Al-Husseini MJ, et al. Causes of death after breast cancer diagnosis: A US population-based analysis. Cancer. 2020;126(7):1559–67.
2. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.
3. Cancer Statistics Center. 2022. https://cancerstatisticscenter.cancer.org/#!/. Accessed 28 Jan 2022.
4. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European countries. Breast Care. 2019;14(6):344–53.
5. Prammer-Waldhör M, Hackl M, Ihle P, Klimont J, Leitner B. Jahrbuch der GESUNDHEITSSTATISTIK. Statistik Austria; 2021.